FDA Peptide Vote 2026: What the Committee Decided

For three years the peptide compounding question sat frozen. FDA had parked a long list of substances in Category 2, the designation reserved for bulk drug substances the agency believes present significant safety risks, and enforcement followed accordingly. In July 2026 that freeze broke. Over two days of public meetings, the Pharmacy Compounding Advisory Committee (PCAC) worked through seven peptide nominations and recommended six of them for inclusion on the Section 503A bulk drug substances list.

The headline is easy to misread. Six favorable votes do not make BPC-157 legal, and they do not change what a vial of research-grade TB-500 is or how it may be sold. What the votes did do is move a stalled regulatory process into its next phase, and set a timetable that anyone sourcing these compounds should now be tracking.

What did the FDA committee actually vote on?

The committee voted on seven separate peptide nominations to the 503A bulk drug substances list, the list that sets what compounding pharmacies may legally compound from. Six were recommended for inclusion and one, emideltide, was rejected.

Each nomination covered the free base and acetate forms of the substance, and each was tied to a specific proposed clinical use. The committee heard FDA’s review, took public comment, then voted. Results across the two days:

Peptide	Proposed use in the nomination	Vote	Outcome
BPC-157	Ulcerative colitis	8 to 6, 1 abstention	Recommended
KPV	Wound healing and inflammatory conditions	8 to 6, 1 abstention	Recommended
TB-500	Wound healing	8 to 6, 1 abstention	Recommended
MOTS-c	Obesity and osteoporosis	7 to 5, 2 abstentions	Recommended
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	8 to 5, 1 abstention	Recommended
Epitalon	Insomnia	7 to 4, 1 abstention	Recommended
Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, narcolepsy	6 to 7, 1 abstention	Not recommended

Two features of that table are worth sitting with. First, the margins are thin. No peptide cleared by more than two votes, and abstentions ran high, which is what a committee looks like when the evidence base is contested rather than settled. Second, the nominated indications are narrow and clinical. BPC-157 was not evaluated as a general tissue repair compound. It was evaluated for ulcerative colitis, which is the use its nominator put forward and the use FDA’s reviewers assessed.

Why FDA’s Own Scientists Opposed All Seven

FDA’s own review team recommended against every one of the seven nominations, and the committee then voted the opposite way on six of them. That split, rather than the vote tallies, is the meeting’s most consequential outcome, because any rulemaking that follows has to reconcile a favourable committee recommendation with a negative internal scientific review.

The most consequential detail of the meeting is one that did not appear in most coverage. FDA’s review team recommended against all seven substances. The committee then voted the opposite way six times.

The agency’s objections clustered into three arguments. The first was insufficient clinical safety and efficacy data, which is the standard finding for compounds whose evidence base is largely preclinical, animal or small open-label work. The second was moiety characterization, meaning FDA was not satisfied that the substance being nominated is consistently and unambiguously the same molecule across suppliers. The third was inadequate adverse event reporting, which is a direct consequence of a market that has operated outside formal pharmacovigilance.

Several committee members who voted in favor attached conditions to their support: authorized API sourcing, mandatory adverse event reporting, and constrained formulations. Those conditions are not self-executing. Whether any of them survive into a proposed rule is one of the open questions of the next year.

The characterization objection is the one most relevant to anyone who buys peptide material. It is a regulator stating, in a public briefing document, that identity and consistency across the supply base cannot currently be assumed. That is the same problem a certificate of analysis exists to solve at the individual lot level, and it is why reading a COA properly matters more in this market than in almost any other.

What a 503A Recommendation Actually Means in Law

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding. A pharmacy may compound from a bulk drug substance only if that substance is the subject of an applicable USP monograph, is a component of an FDA-approved drug, or appears on a list FDA establishes by regulation. That third path is the 503A bulks list, and it is the door these seven peptides were knocking on.

The sequence from here is fixed by administrative law and cannot be skipped:

1. FDA reviews the committee’s recommendations and decides whether to proceed. It is not obligated to follow them, in either direction.
2. FDA publishes a notice of proposed rulemaking naming the substances it intends to add.
3. A public comment period opens, typically 60 to 90 days.
4. FDA reviews comments and issues a final rule.

Only at step four does a substance become legally compoundable under 503A. Firms tracking the docket expect a proposed rule in late 2026 or during 2027, with the full cycle running 12 to 24 months. FDA may also grant interim enforcement discretion while the rule is pending, which would change the practical risk picture for compounders without changing the underlying law.

The important distinction for readers of this site: 503A is about pharmacies compounding prescriptions for identified patients. It is not a licensing scheme for research material, and inclusion on the bulks list would not create one.

How the Category 2 Removal Set This Up

The July meeting did not come out of nowhere. On April 15, 2026, FDA announced that 12 peptides were being removed from Category 2 and confirmed that PCAC would convene in July to consider peptides for the bulks list. Category 2 is the interim classification FDA uses for nominated substances it has determined raise significant safety concerns, and it is the basis on which the agency takes action against compounders distributing them. Category 1 is the opposite end of the same scale: substances under evaluation that have not been flagged for safety risk, where FDA exercises enforcement discretion while review proceeds.

Removal from Category 2 sounds like a green light and is not one. As counsel tracking the docket noted at the time, exiting Category 2 does not by itself place a substance on the bulks list or move it into Category 1. It removes the specific designation that justified enforcement and leaves the substance in an unresolved position until FDA takes final action. April created the opening. July filled it with a recommendation. Neither step is a rule.

Emideltide: The One That Failed, and Why It Matters

Emideltide, better known as delta sleep-inducing peptide or DSIP, lost 6 to 7 with one abstention. A single vote separated it from the six that passed, which tells you the committee was not applying a categorically different standard to it.

What distinguished DSIP was the breadth of its nominated indications. Opioid withdrawal, chronic insomnia and narcolepsy are three distinct clinical problems, two of which have approved therapies and one of which sits in a heavily regulated space. A nomination that asks a committee to accept thin evidence across three indications at once gives every skeptical member something to object to. The narrower nominations fared better.

The practical lesson is that these votes turn substantially on nomination quality and indication scope, not only on the underlying pharmacology. That matters for reading the next round.

What Changes for Research Buyers Right Now

Nothing, legally. It is worth being precise about why, because the gap between the news cycle and the legal reality is where most of the confusion in this market lives.

Material sold as research-grade is sold for laboratory use, not for administration to people. Its status has never depended on the 503A bulks list, because 503A regulates what a licensed pharmacy may compound into a prescription. A favorable bulks list outcome would open a prescription pathway through compounding pharmacies. It would not authorize over-the-counter sale, it would not convert research material into a lawful consumer product, and it would not alter the labeling obligations any vendor already has.

Two second-order effects are worth anticipating, though:

Marketing claims will get looser before the law gets clearer. A favorable committee vote is exactly the kind of event vendors reference to imply approval that has not happened. Expect “FDA panel approved” language on product pages within weeks. It is inaccurate. The committee recommended, the agency has not ruled, and the phrase “FDA approved” means something specific that none of these compounds have.

Supply and pricing may move ahead of the rule. If compounding pharmacies begin positioning for an eventual pathway, demand for pharmaceutical-grade API in these six compounds will rise before any rule is final. BPC-157, TB-500 and KPV are the three most exposed, and all three are already high-volume items in the research market. Anyone budgeting around current pricing should watch that. Our vendor scores and 2026 price analysis track those movements as they happen.

What Comes Next: Rulemaking and the February 2027 Queue

Two threads run in parallel from here.

The first is rulemaking on the six recommended peptides. Watch for a notice of proposed rulemaking in the Federal Register, then for the comment docket. The comment record is where the conditions raised by committee members, particularly authorized API sourcing and adverse event reporting, either become binding requirements or quietly disappear.

The second is the next slate of nominations. Additional peptides are scheduled for review before February 2027, including GHK-Cu, Cathelicidin LL-37, PEG-MGF, Melanotan II and Dihexa acetate. GHK-Cu is the one to watch most closely given how central it is to the current research market and to blended products. Our standing coverage of GHK-Cu and of the GHK-Cu, BPC-157 and TB-500 blend will be updated as that review is scheduled.

A Documentation Checklist for the Interim Period

Regulatory uncertainty raises the value of documentation. If FDA’s own reviewers are unconvinced that the substance in the supply chain is consistently the substance on the label, lot-level evidence is the only thing that closes that gap for an individual buyer.

• Insist on a lot-matched COA. A generic certificate for a product line is not evidence about the vial you received. The lot number on the certificate must match the lot number on the vial.
• Check the analytical methods, not just the purity number. HPLC establishes purity. Mass spectrometry establishes identity. A certificate reporting only the first tells you nothing about whether the molecule is correct.
• Confirm the testing lab is independent. In-house numbers are not third-party verification, and the difference is material.
• Keep records of what you bought and when. If a rule eventually creates documentation requirements, purchase history predating the rule is easier to reconstruct now than later.
• Discount promotional language referencing the vote. A vendor that describes a committee recommendation as FDA approval is telling you something about its compliance posture.

Our vendor review methodology weights COA transparency and third-party testing above price for exactly this reason, and the individual breakdowns for BPC-157, TB-500 and KPV cover what current lab reports actually show for the three compounds most affected by this vote.

Frequently Asked Questions

Did the FDA approve BPC-157 in July 2026?

No. An FDA advisory committee recommended that BPC-157 be added to the 503A bulk drug substances list, by a vote of 8 to 6 with one abstention. A recommendation is not approval, and the 503A list is not a drug approval pathway. BPC-157 remains an unapproved drug substance.

Are peptides legal to buy in the United States after this vote?

The vote did not change what may be sold or to whom. Research-grade peptides continue to be sold for laboratory use only, and none of the seven substances reviewed became a lawful consumer product as a result of the meeting.

What is the 503A bulks list?

It is a list FDA establishes by regulation naming bulk drug substances that licensed pharmacies may use in compounding under Section 503A of the FD&C Act. Substances reach it through nomination, advisory committee review and formal rulemaking.

Why did FDA’s scientists disagree with the committee?

FDA’s review team found insufficient clinical safety and efficacy data, incomplete characterization of the substances themselves, and inadequate adverse event reporting. The committee weighed the same record differently and recommended six of the seven anyway.

When will there be a final decision?

FDA must publish a proposed rule, take public comment for a period usually running 60 to 90 days, and issue a final rule. Practitioners tracking the process estimate 12 to 24 months from here, with a proposed rule expected in late 2026 or 2027.

Which peptides are up for review next?

GHK-Cu, Cathelicidin LL-37, PEG-MGF, Melanotan II and Dihexa acetate are scheduled for review before February 2027.

Does this affect WADA status or sports eligibility?

No. Anti-doping prohibitions are set by WADA and the relevant sports bodies, independently of FDA classification. A change in compounding status would not alter a substance’s prohibited status in competition.

References

1. U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Advisory Committee Calendar and briefing materials.
2. McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” July 2026.
3. Hyman, Phelps & McNamara, FDA Law Blog. “The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List.” July 2026.
4. Orrick. “FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List.” April 2026.
5. Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
6. National Community Pharmacists Association. “FDA advisory committee nominates six peptides for pharmacies to compound.” July 31, 2026.

Peptide Insider publishes market and regulatory analysis for laboratory professionals. This article is informational and is not legal advice, medical advice, or a recommendation to purchase or use any substance. Compounds discussed here are not approved for human use.

Primary sources

• Characterization of structurally related peptide impurities. 2022 (PMID 35840670)
• Characterization of Synthetic Peptide Therapeutics Using Mass Spectrometry. 2021 (PMID 34110145)
• Aspects of complexity in quality and safety assessment of peptide therapeutics. 2024 (PMID 39243929)
• Establishment of a validated stability-indicating purity method. 2021 (PMID 33823624)
• FDA. Certain Bulk Drug Substances for Compounding May Present Significant Safety Risks